anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Qsymia
Trial phase: Phase 4
ATC code: A08AA51
SMILES: CC(C)(N)Cc1ccccc1.CC1(C)OC2COC3(COS(N)(=O)=O)OC(C)(C)OC3C2O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 42
Group description: Phentermine-Topiramate Extended Release: Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily

Online support system: VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices that was used as part of this study. It also allowed subjects to document study medication compliance and allowed the remote visits to be conducted through a video conference between subjects and appropriate study team members.
Eligibility criteria:
Inclusion Criteria

Adults with obesity (BMI >30Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and controlled comorbidities or other diseases.
Age: 18-75 years.
Gender: Men or women. Women of childbearing potential will have negative pregnancy tests within 48 hours of enrollment.
Women of childbearing potential must agree to use a method of effective contraception during study participation.
Subject must have an Apple iPhone 6s or later with iOS 13 or later and be willing to download the VitalCare (VitalTech Affiliates LLC) application from the Apple App Store.
Able to provide written informed consent prior to any study procedures, and be willing and able to comply with study procedures

Exclusion Criteria

History of Abdominal bariatric surgery
Weight is greater than 450 lbs (204 kg)
Recent use (within the last three months) of any antiobesity medication
Recent weight change (gain or loss weight greater than 3% TBW in the last 3 months)
Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat, within the last 6 months.
Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.
Hypersensitivity or contraindication to the study medication.
Participant unable or unwilling to follow protocol including use of the wearable activity tracker, digital wellness devices, VitalCare application, or unwilling to sign consent.
Principal Investigator discretion
Intervention: HYDROGEN PEROXIDE
Trial phase: Phase 2
ATC code: A01AB02 | D08AX01 | D11AX25 | S02AA06
SMILES: OO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)
Eligibility criteria:
Inclusion Criteria:

Tested positive for COVID-19 with a sample collected in the prior 7 days
Ability to read and speak English or Spanish
Ability to participate in the study for 4 weeks
Being asymptomatic or having mild or moderate symptoms (for example, sore throat, coughing, fever, fatigue)
Ability to rinse/gargle
Not having any condition that might worsen with gargling solutions
Not having a history of mouthwash sensitivity
Not having an allergy to any mouthwash that has been used before
Not using another mouthwash/gargling solution since the most recent positive test
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics including off-label FDA-approved medications such as hydroxychloroquine)
Anticipated ability to participate in the study for 4 weeks
Have a cellphone and agree to receive text messages for reminders to use mouthwash during the day and for follow-up visits, and can videoconference (like zoom) on a cellphone, tablet, or computer for sample collection instructions

Exclusion Criteria:

People who because of their symptoms intend to receive antiviral medications that could potentially affect viral load in their saliva samples
Pregnant or lactating women due to potential aversions to mouthwash solution taste/smell.
Intervention: Cetylpyridinium Chloride
Trial phase: Phase 2
SMILES: CCCCCCCCCCCCCCCC[n+]1ccccc1.[Cl-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)
Eligibility criteria:
Inclusion Criteria:

Tested positive for COVID-19 with a sample collected in the prior 7 days
Ability to read and speak English or Spanish
Ability to participate in the study for 4 weeks
Being asymptomatic or having mild or moderate symptoms (for example, sore throat, coughing, fever, fatigue)
Ability to rinse/gargle
Not having any condition that might worsen with gargling solutions
Not having a history of mouthwash sensitivity
Not having an allergy to any mouthwash that has been used before
Not using another mouthwash/gargling solution since the most recent positive test
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics including off-label FDA-approved medications such as hydroxychloroquine)
Anticipated ability to participate in the study for 4 weeks
Have a cellphone and agree to receive text messages for reminders to use mouthwash during the day and for follow-up visits, and can videoconference (like zoom) on a cellphone, tablet, or computer for sample collection instructions

Exclusion Criteria:

People who because of their symptoms intend to receive antiviral medications that could potentially affect viral load in their saliva samples
Pregnant or lactating women due to potential aversions to mouthwash solution taste/smell.
Intervention: Chlorine Dioxide
Trial phase: Phase 2
SMILES: [O][Cl+][O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Over the counter: CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)
Eligibility criteria:
Inclusion Criteria:

Tested positive for COVID-19 with a sample collected in the prior 7 days
Ability to read and speak English or Spanish
Ability to participate in the study for 4 weeks
Being asymptomatic or having mild or moderate symptoms (for example, sore throat, coughing, fever, fatigue)
Ability to rinse/gargle
Not having any condition that might worsen with gargling solutions
Not having a history of mouthwash sensitivity
Not having an allergy to any mouthwash that has been used before
Not using another mouthwash/gargling solution since the most recent positive test
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics including off-label FDA-approved medications such as hydroxychloroquine)
Anticipated ability to participate in the study for 4 weeks
Have a cellphone and agree to receive text messages for reminders to use mouthwash during the day and for follow-up visits, and can videoconference (like zoom) on a cellphone, tablet, or computer for sample collection instructions

Exclusion Criteria:

People who because of their symptoms intend to receive antiviral medications that could potentially affect viral load in their saliva samples
Pregnant or lactating women due to potential aversions to mouthwash solution taste/smell.
Intervention: SODIUM FLUORIDE
Trial phase: Phase 2
ATC code: A01AA01 | A01AA51 | A12CD01 | V09IX06
SMILES: [F-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Over the counter: Listerine Zero (Alcohol-Free)(Johnson and Johnson, USA) (C30H52O3)
Eligibility criteria:
Inclusion Criteria:

Tested positive for COVID-19 with a sample collected in the prior 7 days
Ability to read and speak English or Spanish
Ability to participate in the study for 4 weeks
Being asymptomatic or having mild or moderate symptoms (for example, sore throat, coughing, fever, fatigue)
Ability to rinse/gargle
Not having any condition that might worsen with gargling solutions
Not having a history of mouthwash sensitivity
Not having an allergy to any mouthwash that has been used before
Not using another mouthwash/gargling solution since the most recent positive test
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics including off-label FDA-approved medications such as hydroxychloroquine)
Anticipated ability to participate in the study for 4 weeks
Have a cellphone and agree to receive text messages for reminders to use mouthwash during the day and for follow-up visits, and can videoconference (like zoom) on a cellphone, tablet, or computer for sample collection instructions

Exclusion Criteria:

People who because of their symptoms intend to receive antiviral medications that could potentially affect viral load in their saliva samples
Pregnant or lactating women due to potential aversions to mouthwash solution taste/smell.
Intervention: Thymol
Trial phase: Phase 2
SMILES: Cc1ccc(C(C)C)c(O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days

Essential oils: Gargle
Eligibility criteria:
Inclusion Criteria:

adult aged 18 years and above
able to understand instructions
Stage 1 COVID-19
< 5 days of illness or diagnosis

Exclusion Criteria:

Less than 18 years old
Unable to understand instructions
Stage 2 & 3 COVID-19
Respiratory symptoms or fever on admission
Abnormal chest radiograph or computed tomography (CT) findings on admission
Intervention: Roxadustat
Trial phase: Phase 3
ATC code: B03XA05
SMILES: Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 203
Group description: Participants received roxadustat as an oral tablet, TIW for up to a maximum of 24 weeks. If a participant required roxadustat <60 mg/week to maintain Hb levels, the dose frequency was reduced in a stepwise manner, for example, to BIW, and then QW. For participants converted from CERA, the initial roxadustat dose was based on the average prescribed CERA dose in the last 8 weeks prior to conversion. For participants with <6 weeks of prior CERA use, the initial roxadustat dose was based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations were made every 4 weeks and doses were titrated based on Hb level and rate of Hb change. The prescribed dose did not exceed the maximum allowable dose of 3.0 mg/kg/dose or 400 mg per dose, whichever was lower.
Eligibility criteria:
Key Inclusion Criteria:

Receiving chronic dialysis for end stage renal disease (ESRD)
Vascular access must be a functioning native arteriovenous fistula or graft with adequate flow in the opinion of the investigator, or permanent tunneled catheter
Screening hemoglobin criteria (based on central lab value; measured within 10 days prior to initiating Roxadustat treatment: Participants converting from CERA: screening heamoglobin was between 9.0 to 12.0 g/dL; Participants initiating anemia treatment: <10.0 g/dL
Ferritin ≥ 50 nanograms (ng)/milliliter (mL), Transferrin saturation (TSAT) ≥ 10% at screening
Participant's alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are ≤3 x upper limit of normal (ULN), and total bilirubin (TBL) is ≤1.5 x ULN at screening and prior to initiating roxadustat treatment.
Body weight between 45.0 to 160.0 kg

Key Exclusion Criteria:

Red blood cell (RBC) transfusion within 4 weeks prior to enrollment
Known history of myelodysplastic syndrome or multiple myeloma
Known hereditary hematologic disease or other known causes for anemia other than chronic kidney disease (CKD)
Known chronic inflammatory disease that is determined by the investigator to be the primary cause of anemia
Active or chronic gastrointestinal bleeding
Treated with iron-chelating agents within 4 weeks prior to enrollment
History of New York Heart Association (NYHA) Class III or IV congestive heart failure
History of myocardial infarction (MI), acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (excluding vascular dialysis access stenosis/thrombosis) within 12 weeks prior to enrollment
Uncontrolled hypertension, in the opinion of the Investigator
Diagnosis or suspicion of renal cell carcinoma as shown on renal imaging performed within 24 weeks prior to enrollment
History of malignancy, except for cancers determined to be cured or in remission for ≥2 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
Intervention: Levothyroxine
Trial phase: Phase 3
ATC code: C10AX01 | H03AA01 | H03AA51
SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 419
Group description: Intravenous thyroxine infusion

Thyroxine: Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.

Donors were followed till organ recovery or end of management.
Eligibility criteria:
Inclusion Criteria:

Declared dead by neurologic criteria (brain dead)
Authorization for organ donation and research
On one or more vasopressors and/or inotropes

Exclusion Criteria:

Brain death declared more than 24 hours prior
Only vasopressor is vasopressin
Weight < 45 kg (100 lbs)
Known coronary artery disease or history of myocardial infarction
Known valvular heart disease
Prior sternotomy or cardiac surgery
Donor at VA hospital
Received intravenous or oral thyroxine within past month
Known HIV+ status
Other reason donor is unable to receive study drug (determined by on-site personnel)
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 419
Group description: Intravenous saline infusion

Saline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.

Donors were followed till organ recovery or end of management.
Eligibility criteria:
Inclusion Criteria:

Declared dead by neurologic criteria (brain dead)
Authorization for organ donation and research
On one or more vasopressors and/or inotropes

Exclusion Criteria:

Brain death declared more than 24 hours prior
Only vasopressor is vasopressin
Weight < 45 kg (100 lbs)
Known coronary artery disease or history of myocardial infarction
Known valvular heart disease
Prior sternotomy or cardiac surgery
Donor at VA hospital
Received intravenous or oral thyroxine within past month
Known HIV+ status
Other reason donor is unable to receive study drug (determined by on-site personnel)
Intervention: Tacrolimus
Trial phase: Phase 2
ATC code: D11AH01 | L04AD02
SMILES: C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Envarsus XR to be initiated once patient is tolerating oral medications

Extended-Release Tacrolimus: Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.
Eligibility criteria:
Inclusion Criteria:

Prospective arm:

Age ≥ 18 years
Received a lung transplant at NYU Langone Health
Be able to convert to Envarsus XR within the first month post-transplant
Able and willing to provide informed consent

Historical control:

Age ≥ 18 years
Received a lung transplant at NYU Langone Health
Completed one year from transplant on IR tacrolimus

Exclusion Criteria:

Prospective arm:

Contraindication to tacrolimus due to allergic or adverse reactions
Pregnant or nursing women
Multi-organ transplant recipient

Historical control:

Contraindication to tacrolimus due to allergic or adverse reactions (not including chronic kidney disease)
Intervention: Ozone
Trial phase: Not Applicable
SMILES: O=[O+][O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 63
Group description: The patients in the ozone injection (OI) group received injections on the 1st, 4th, 7th and 10th days. A gas mixture containing 10 cc of 5% O3 and 95% medical O2 at a concentration of 25 μg/ml in the first application, 20 μg/ml in the second application, and 15 μg/ml in the third and fourth applications was used. It was the same physician who prepared and administered ozone. Experience has shown that a single dose of ozone application is not sufficient, it must be applied in sessions for a strong effect. Therefore, we used 4 doses of OI instead of a single dose in our study.
Eligibility criteria:
Inclusion Criteria:

Over 18 years of age, under 75 years of age
Lateral hip pain
Having pain for at least 3 months
The VAS value should be minimum 4 and pain is increased by pressing on t.major.
Conservative treatment failure

Exclusion Criteria:

Motor and / or sensory impairment compatible with radiculopathy
Connective tissue disease
Pregnancy
Active infection, immune system disorders, unresolved fractures
Hip op history, bursectomy / ilio-tibial band elongation
Steroid injection history in the past 4 months
Physical therapy history for trochanteric bursitis in the last 4 months
Rheumatological patients, pregnancy, Patients with a history of cancer
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 63
Group description: A single dose injection was given to the patients in the corticosteroids (CSI) group. The solution to be administered to the CSI group was obtained by mixing 1 ml of 2% lidocaine and 1 ml of betamethasone (Diprospan 2 mg/1ml+5 mg/1ml). It was the same physician who prepared and administered the solutions. In the studies, it was generally applied as a single dose and mixed with local anesthetic (LA). Therefore, in our study, we also applied it as a single dose by mixing it with LA.
Eligibility criteria:
Inclusion Criteria:

Over 18 years of age, under 75 years of age
Lateral hip pain
Having pain for at least 3 months
The VAS value should be minimum 4 and pain is increased by pressing on t.major.
Conservative treatment failure

Exclusion Criteria:

Motor and / or sensory impairment compatible with radiculopathy
Connective tissue disease
Pregnancy
Active infection, immune system disorders, unresolved fractures
Hip op history, bursectomy / ilio-tibial band elongation
Steroid injection history in the past 4 months
Physical therapy history for trochanteric bursitis in the last 4 months
Rheumatological patients, pregnancy, Patients with a history of cancer
Intervention: Afamelanotide
Trial phase: Phase 2
ATC code: D02BB02
SMILES: CCCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(C)=O)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(N)=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.

Afamelanotide
Eligibility criteria:
Inclusion Criteria:

Male or female Caucasian subjects undergoing photodynamic therapy with porfimer sodium;
Aged greater than 18 years;
Written informed consent prior to the performance of any study-specific procedure.

Exclusion Criteria:

Known allergy or hypersensitivity to afamelanotide or the polymer contained in the implant;
Non-Caucasian patients;
Personal history of melanoma or dysplastic nevus syndrome;
Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions;
Female who is pregnant (confirmed by positive serum β-HCG pregnancy test prior to baseline) or lactating;
Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device);
Participation in a simultaneous clinical trial for another investigational agent or within 30 days prior to the screening visit;
Patients unable to give informed consent;
Patient needs for concomitant medication with potential photosensitizing effects e.g. antibiotics like tetracyclines.
Intervention: Bupivacaine
Trial phase: Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 148
Group description: Up to 60ml of 0.25% bupivacaine was injected directly into each of the port sites and specimen extraction site at the conclusion of the procedure prior to skin closure.
Eligibility criteria:
Inclusion Criteria:

Age 18 years or older
Undergoing Robotic Assisted Laparoscopic Partial Nephrectomy or Robotic Assisted Laparoscopic Prostatectomy
Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

Prior Partial Nephrectomy or Subtotal Prostatectomy Surgery (organ specific)
Conversion to open surgery
History of chronic pain
History of opiate or alcohol dependence
Allergies to local anesthetic
Retroperitoneal surgery
Single Port Surgery
Intervention: Methionylmethionylarginine
Trial phase: Not Applicable
SMILES: CSCCC(N)C(=O)NC(CCSC)C(=O)NC(CCCN=C(N)N)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: All Group A patients will receive intralesional MMR.

Measles-Mumps-Rubella Vaccine: Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
Eligibility criteria:
Inclusion Criteria:

1. Clinically diagnosed patients who have more than three warts or single wart in difficult to treat sites (periungual, palms and soles)

Exclusion Criteria:

Patients not under any systemic or topical treatment of warts for the last four weeks
Patients with a past history of an allergic response to MMR or any other vaccine or Vitamin D
Patients with current acute febrile illness or any bacterial infection
Immunosuppressed patients
Pregnant or lactating women
Patients having a past history of asthma, allergic skin disorders or convulsions
Patients with keloidal tendency
Patient refusal for consent
Treating physician's decision to give other treatment modality
Patients with hypervitaminosis D, muscle weakness, bone pain, altered sensorium